Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer signals ...

Stifel lowered the firm’s price target on Sage Therapeutics (SAGE) to $6 from $10 and keeps a Hold rating on the shares. 2024 was “a challenging year,” with shares down about 75% following the failure ...

Sage Group plc ( ($GB:SGE) ) has issued an update. Sage Group plc has continued to execute its previously announced share buyback programme, ...

RBC Capital analyst Brian Abrahams raised the firm’s price target on Sage Therapeutics (SAGE) to $5 from $4 and keeps a Sector Perform rating on the shares as part of a broader research note ...

In recent trading, shares of Sage Therapeutics Inc (Symbol: SAGE) have crossed above the average analyst 12-month target price of $179.14, changing hands for $180.53/share. When a stock reaches the ...

I was pinged this morning about an angry piece written at LinkedIn by Tim Rodman, ERP Systems Analyst at The Robbins Company. The target of Rodman's ire is Sage and specifically a Sage 500 price ...

In what some will consider a breathtaking moment of utter madness, Sage UK is imposing substantial price hikes for its core Sage 50 range of SMB on premises solutions. These range from 67% to 90%.

Shares of Cambridge-based drugmaker Sage Therapeutics tanked almost 64% on Thursday morning after the company posted disappointing results for a key drug trial. The $7.7 billion pharmaceutical company ...